The company will use the proceeds to test its gene therapy XC001 in two Phase II studies involving patients with cardiovascular disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback